While initial reports suggested that EZH2 impacts metastasis progression through non-canonical pathways independent of EZH2 methyltransferase activity (i.e. p38 signalling and integrin B1-FAK) [13, 14], later studies supported that the role of EZH2 in breast cancer is based on the H3K27me3-mediated transcriptional repression of key candidate genes (ie. FOXC1 or GATA3) [15, 16]. The gene discussed is EZH2; the disease is breast cancer.